Close Menu

NEW YORK – Roche announced Friday that its Cobas SARS-CoV-2 & Influenza A/B test received Emergency Use Authorization from the US Food and Drug Administration. 

The RT-PCR test runs on Roche's Cobas 6800/8800 systems and is intended to qualitatively detect and differentiate SARS-CoV-2, influenza A, and influenza B from one nasal or nasopharyngeal sample. The multiplex test is also available in countries accepting the CE mark.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.